Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants

Inclusion Criteria: * The participant has a BMI ≥18.5 and ≤25 kilograms (kg)/square meter (m\^2) or ≤30 kg/m\^2 for Japanese and Caucasian participants, respectively, and a body weight ≥50 kilograms (kg) at the screening visit and at the baseline visit. * The participant is, in the opinion of the investigator, generally healthy based on medical history, a physical examination, a neurological examination, vital signs, electrocardiograms (ECG), and the results of the clinical chemistry, haematology, urinalysis, serology, and other laboratory tests. Exclusion Criteria: * The participant has taken disallowed medication \<1 week prior to the first dose of study drug or \<5 half-lives of the disallowed medication as concomitant use prior to the screening visit. * The participant has or has had any clinically significant immunological, cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, hematological, dermatological, venereal, neurological, or psychiatric disease or other major disorder. * The participant has had a clinically significant illness \<4 weeks prior to the first dose of study drug. * The participant has received a SARS-CoV-2 (COVID-19) vaccination \<30 days prior to the first dose of study drug. Note: Other inclusion and exclusion criteria may apply.